Did you know there is a startup company that is developing a portfolio of therapies to address all core cells of the human body to extend human lifespan and healthspan by 10+ years, and if successful, the potential to extend lifespan and healthspan by decades or even centuries.
This Startup company is Retro Bio.
Retro Bio is co-founded by Sam Altman, CEO of OpenAI / Former CEO of Y Combinator, who is personally investing $180M.
Solution: Retro Bio’s therapies target the root cause of aging, capable of significantly slowing down aging and/or reserve aging, using epigenetic reprogramming and cell replacement therapies, and uses an AI approach, in partnership with OpenAI, to test and develop therapies.
Traction: Retro Bio has developed a portfolio of 19 therapies covering a wide range of cells of the human body, and is rapidly moving into trials for its first three therapies: Alzheimer’s, blood, and central nervous system diseases, with a first-in-human Alzheimer’s trial in Q4 2025, and the next two therapies have first-in-human trials happening in Q4 2026.
Retro Bio has already had a major breakthrough showing a 50x increase in efficiency of epigenetic reprogramming. The Net Present Value (NPV) of the first three therapies is $14B, and the broader NPV across its 19 therapies is $50B – $100B+ in revenues.
Currently, you have the chance of investing in this startup as long as it is showing in our “Investment Opportunities” page. Contact Us to get more details
